
Bio-Path Investor Relations Material
Latest events

Q3 2023
Bio-Path
Access the full event backlog
Slides, Transcripts, and Reports from over 8,000 public companies
Bio-Path Holdings, Inc. is a clinical and preclinical stage oncology focused RNAi nano particle drug development company that operates in the United States. The Company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. Bio-Path Holdings, Inc. was founded in 2007 and is headquartered in Bellaire, Texas.
Latest articles

Webull vs Robinhood: Which Platform Suits You?
In the competitive world of online trading platforms, Webull and Robinhood have emerged as two of the top choices for investors.
24 Nov 2023

Norway's Sovereign Wealth Fund: Transforming Oil Wealth into Lasting Prosperity
But what makes Norway’s striking of oil so fundamentally different from its worse faring counterparts? The answer is in large part its Norwegian Government Pension fund, and Norges Bank Investment Management
24 Nov 2023

Danaher Business System and Acquisition History
Since the early 1990s, Danaher's management team has transformed a group of under-performing industrial manufacturing companies into a global powerhouse in life sciences and diagnostics.
22 Nov 2023
Ticker symbol
BPTH
Country
🇺🇸 United States